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Abstract
Genome-wide association studies (GWAS) have recently identified KIF1B as susceptibility locus for hepatitis B virus (HBV)–
related hepatocellular carcinoma (HCC). To further identify novel susceptibility loci associated with HBV–related HCC and
replicate the previously reported association, we performed a large three-stage GWAS in the Han Chinese population.
523,663 autosomal SNPs in 1,538 HBV–positive HCC patients and 1,465 chronic HBV carriers were genotyped for the
discovery stage. Top candidate SNPs were genotyped in the initial validation samples of 2,112 HBV–positive HCC cases and
2,208 HBV carriers and then in the second validation samples of 1,021 cases and 1,491 HBV carriers. We discovered two
novel associations at rs9272105 (HLA-DQA1/DRB1) on 6p21.32 (OR=1.30, P=1.13610
219) and rs455804 (GRIK1) on 21q21.3
(OR=0.84, P=1.86610
28), which were further replicated in the fourth independent sample of 1,298 cases and 1,026
controls (rs9272105: OR=1.25, P=1.71610
24; rs455804: OR=0.84, P=6.92610
23). We also revealed the associations of HLA-
DRB1*0405 and 0901*0602, which could partially account for the association at rs9272105. The association at rs455804
implicates GRIK1 as a novel susceptibility gene for HBV–related HCC, suggesting the involvement of glutamate signaling in
the development of HBV–related HCC.
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Hepatocellular carcinoma (HCC) is the sixth common cancer
and the third common cause of cancer mortality worldwide [1].
The incidence rate of HCC varies considerably in the world, with
the highest in East, Southeast Asia and Sub-Saharan Africa, and
China alone accounts for approximately half of HCC malignan-
cies [1,2]. Major risk factors for HCC are chronic infections with
the hepatitis B or C viruses, and exposure to dietary aflatoxin B1.
Hepatitis B virus (HBV) infection is particular important, because
of its coherent distribution with the HCC prevalence [1,2].
However, it is known that only a minority of chronic carriers of
HBV develop HCC [3], and the chronic HBV carriers with a
family history of HCC have a two-fold risk for HCC than those
without the family history [4], strongly suggesting the importance
of genetic susceptibility for HBV-related HCC.
A number of candidate genes were investigated by genetic
association studies to evaluate their roles in the susceptibility to
HCC [5]. However, the findings from these studies are
inconclusive due to moderate evidence and lack of independent
validation. Recently, a genome-wide association study (GWAS) of
HBV-related HCC was performed [6], in which 355 HBV–
positive HCC patients and 360 chronic HBV carriers were used
for the genome-wide discovery analysis, and the top 45 SNPs from
the discovery analysis were further evaluated in additional 1,962
HBV–positive HCC patients and 1,430 controls (both chronic
HBV carriers and population controls) as well as 159 trios. The
study identified KIF1B as a novel susceptibility locus (top SNP
rs17401966) on 1p36.22. Further study with better design and
bigger sample size was recommended for identifying additional
susceptibility loci for HCC [7,8]. These motivate us to carry out a
GWAS with a large sample size in Chinese population to discover
novel susceptibility loci for HCC.
Results
We performed a genome-wide discovery analysis by analyzing
523,663 common autosomal SNPs in two independent cohorts of
the Han Chinese: 480 cases and 484 controls from central China
and 1058 cases and 981 controls from southern China (Table S1
and Figure S1). The principal component analysis (PCA)
confirmed all the samples to be Chinese, but indicated moderate
genetic mismatch between the cases and controls in the cohort of
southern China (Figure S2). To minimize the effect of population
stratification, we performed the genome-wide association analysis
using PCA-based correction for population stratification. After the
adjustment by the first principal component, the lgc of the
genome-wide association results is 1.013 for the cohort of central
China, 1.003 for the cohort of southern China and 1.012 for the
combined samples. Furthermore, for all the three genome-wide
analyses of central, southern and combined samples, the quantile-
quantile (QQ) plot of the observed P values revealed a good overall
fit with the null distribution (Figure S3). Taken together, these
results clearly indicate that the final association results from our
genome-wide discovery analysis are free of inflation effect due to
population stratification.
The genome-wide discovery analysis revealed multiple sugges-
tive associations (P,10
25) on 2q22.1, 6p21.32, 11p15.1 and
20q12 (Figure S4 and Table S2). To validate these findings, 39
SNPs were selected according to their overall association evidence
in three GWAS analyses as well as their consistencies of association
between the two independent GWAS samples (Central and
Southern China) (see the Methods for the selection criteria). The
39 SNPs were genotyped in additional 2,112 HBV–positive HCC
cases and 2,208 HBV carriers (Phase I validation) (Table S1). Of
the 39 SNPs, only 3 (rs9272105 on 6p21.32, rs11148740 on
13q21.32 and rs455804 on 21q21.3) were validated, showing
consistent association between the GWAS discovery and Phase I
validation samples (Table S3). These 3 SNPs were then genotyped
in additional 1,021 HBV–positive HCC cases and 1,491 HBV
carriers (Phase II validation). The Phase II validation analysis
(Table 1) confirmed the associations at rs9272105 on 6p21.32
(OR=1.41, P=7.63610
29) and rs455804 on 21q21.3
(OR=0.83, P=3.63610
23), but not the association at
rs11148740 on 13q21.32 (Table S3).
For both rs9272105 and rs455804, no heterogeneity of
associations were observed among the GWAS and validation
samples (P.0.05), and the associations in the combined GWAS
and validation samples achieved genome-wide significance
(P,5.0610
28) (rs9272105: OR=1.30, P=1.13610
219 and
rs455804: OR=0.84, P=1.86610
28) (Table 1). As a replication,
these two SNPs were genotyped in the fourth independent samples
of 1,298 cases and 1,026 controls from central China, which
further confirmed the associations at rs9272105 (OR=1.25,
P=1.71610
24) and rs11148740 (OR=0.84, P=6.92610
23)
(Table 1). When combining all the five groups of samples, the
two SNPs resulted in a 28% increased, and a 16% decreased risk
for HCC development (rs9272105: OR=1.28, P=5.24610
222
and rs455804: OR=0.84, P=5.24610
210) (Table 1), respectively.
The associations at the two SNPs remained genome-wide
significant after adjusting for age, gender, smoking and drinking
(Table S4A). Furthermore, stratification analysis by age, gender,
smoking and drinking status revealed similar ORs for rs9272105
and rs455804 among subgroups, except that the association at
rs9272105 showed a stronger effect in the non-smoking group than
the smoking one (OR=1.38 vs. 1.19, P for heterogeneity=0.004)
(Table S4B). Pair-wise interaction analysis among these two SNPs,
smoking and drinking status did not reveal any significant
interaction (data not shown). The samples used in the GWAS,
validation and replication analyses are summarized in Table S1,
and the multi-stage design of the whole study is shown in Figure
S5.
We further investigated the association of HLA alleles in our
GWAS samples through imputation. After QC filtering (see the
Methods), 37 HLA alleles were successfully imputed, and 5 alleles
showed nominal association (P,0.05) (Table S5 and Table 2).
Further stepwise conditional analysis revealed that only two DRB1
Author Summary
Previous studies strongly suggest the importance of
genetic susceptibility for hepatocellular carcinoma (HCC).
However, the studies about genetic etiology on HBV–
related HCC were limited. Our genome-wide association
study included 523,663 autosomal SNPs in 1,538 HBV–
positive HCC patients and 1,465 chronic HBV carriers for
the discovery analysis. 2,112 HBV–positive HCC cases and
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and 1,491 HBV carriers (the second validation), were then
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1,298 cases and 1,026 controls were analyzed as replica-
tion. We discovered two novel associations at rs9272105
(HLA-DQA1/DRB1) on 6p21.32 and rs455804 (GRIK1)o n
21q21.3. HLA-DRB1 molecules play an important role in
chronic HBV infection and progression to HCC. The
association at rs455804 implicates GRIK1 as a novel
susceptibility gene for HBV–related HCC, suggesting the
involvement of glutamate signaling in the development of
HBV–related HCC.
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P=6.18610
24; DRB1*0901: OR=0.82, P=3.62610
23)
(Table 2). Conditioning on rs9272105 could abolish the associa-
tions of the DRB1 alleles, and conditioning on the DRB1 alleles
could weaken, but not eliminate, the association at rs9272105
(Table 2). The haplotype analysis of rs9272105 and the two DRB1
alleles revealed consistent result, showing that both the DRB1
alleles sit on the haplotypes carrying the protective G allele of
rs9272105 (Table S6). Taking together, there seems to be
additional risk effect beyond the ones carried by the DRB1 alleles.
We further explored whether the SNPs rs9272105 and rs455804
play any role in HBV infection. First, we compared the
frequencies of these 2 SNPs between 408 non-symptomatic
HBV carriers and 521 symptomatic chronic HBV patients from
southern China (GWA scanned). The analysis revealed a
protective effect at rs9272105 (OR=0.80, P=1.67610
22)o n
the development of symptomatic chronic hepatitis B, but no
association at rs455804 (Table S7A). Furthermore, we genotyped
these 2 SNPs in 1,344 individuals with HBV nature clearance and
compared their frequencies with those in 4,183 asymptomatic
HBV carriers (all from the Central China). The analysis also
revealed a protective association at rs9272105 for HBV chronic
infection (OR=0.88, P=3.78610
23) (Table S7B).
Discussion
SNP rs9272105 is located between HLA-DQA1 and HLA-DRB1
on 6p21.32 (Figure 1A). SNP imputation in the GWAS discovery
samples revealed additional SNPs showing association, but
rs9272105 remained to be the top SNP within the region
(Figure 1A). The residual association at rs9272105 after condi-
tioning the association effects of the HLA alleles DRB1*0405 and
*0901 suggests that there may be additional risk effect beyond the
DRB1 alleles in Chinese population. The associations of the DRB1
alleles revealed by this study are consistent with the previous
reports that HLA-DQ/DR alleles associated with HCC risk [9,10].
In addition, we investigated the previously reported HBV
infection-associated SNPs rs3077, rs9277535, rs7453920, and
rs2856718 within the HLA DP/DQ region [11,12] with HCC
development in our GWAS samples. By imputation, we found the
evidence of the association at rs9277535 with HCC (rs9277535:
OR=0.85, P=7.9610
23). However, there is no linkage disequi-
librium (LD) between rs9277535 and our SNP rs9272105
(r
2=0.016 according the HapMap CHB+JPT samples), suggesting
that the associations at rs9277535 and rs9272105 may be
independent.
The HLA-DQ locus has also been shown to be associated with
HCV-related HCC in a Japanese GWAS (rs9275572, OR=1.30,
P=9.38610
29) [13]. SNPs rs9275572 and rs9272105 are 79 kb
away from each other and in weak LD (D9=0.43, r
2=0.08 in the
HapMap CHB samples). The SNP rs9275572 did not show any
association with HBV-related HCC in our GWAS discovery
samples (OR=0.93, P=0.24) (Table S8 and Figure S6B). In
addition to HLA-DQ, MICA (rs2596542) on 6p21.33 and DEPDC5
(rs1012068) on 22q12.3 were also identified as independent
susceptibility loci for HCV-related HCC in Japanese population
Table 1. Summary of GWAS scan, validation, and replication studies for the 2 SNPs.
SNP Study Cases
b (n=5,969) Controls
b (n=6,190) MAF
c
OR (95% CI)
d P
d P_Q
e
cases controls
6p21.32:
rs9272105
GWAS Southern 348/456/251 239/450/286 0.55 0.48 1.28(1.13–1.46) 1.80E-04
A/G
a GWAS Central 129/229/122 81/249/154 0.51 0.42 1.41(1.16–1.72) 6.45E-04
Joint GWAS 477/685/373 320/699/440 0.53 0.46 1.32(1.19–1.46) 2.26E-07 6.20E-01
Validation 1 580/976/556 436/1118/653 0.51 0.45 1.24(1.14–1.35) 5.15E-07
Validation 2 278/420/242 260/770/459 0.52 0.43 1.41(1.25–1.58) 7.63E-09
Joint Validation 858/1396/798 696/1888/1112 0.51 0.44 1.30(1.21–.139) 8.73E-14 8.10E-02
GWAS+Validation 1&2 1335/2081/1171 1016/2587/1552 0.52 0.45 1.30 (1.23–1.38) 1.13E-19 3.36E-01
Replication 335/621/342 195/516/315 0.50 0.44 1.25(1.11–1.40) 1.71E-04
All combined 1670/2702/1513 1211/3103/1867 0.51 0.45 1.28(1.22–1.35) 5.24E-22 3.88E-01
21q21.3:
rs455804
GWAS Southern 110/397/551 126/440/415 0.29 0.35 0.74(0.64–0.85) 3.37E-05
A/C
a GWAS Central 47/215/218 56/215/213 0.32 0.34 0.94(0.76–1.16) 5.54E-01
Joint GWAS 157/612/769 182/655/628 0.30 0.35 0.81(0.72–0.90) 1.65E-04 1.09E-01
Validation 1 201/888/1021 262/962/976 0.31 0.34 0.87(0.79–0.95) 1.62E-03
Validation 2 89/426/506 154/689/648 0.30 0.33 0.83(0.74–0.94) 3.63E-03
Joint Validation 290/1314/1527 416/1651/1624 0.30 0.34 0.85(0.79–0.92) 2.05E-05 5.41E-01
GWAS+Validation 1&2 447/1926/2296 598/2306/2252 0.30 0.34 0.84 (0.79–0.89) 1.86E-08 3.15E-01
Replication 123/530/645 106/476/444 0.30 0.34 0.84(0.74–0.95) 6.92E-03
All combined 570/2456/2941 704/2782/2696 0.30 0.34 0.84(0.80–0.89) 5.24E-10 3.14E-01
aMinor allele/major allele;
bVariant homozygote/Heterozygote/Wild type homozygote;
cMinor allele frequency (MAF);
dAdjusted by the first principal component;
eP value of heterogeneity based on Cochrane’s Qtest.
doi:10.1371/journal.pgen.1002791.t001
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supportive evidence for these two loci (rs2596542: OR=1.06,
P=0.36; and rs1012068: OR=1.06, P=0.37) (Table S8 and
Figure S6C and S6D). We also evaluated the power of our GWAS
discovery samples and found that our samples should have
sufficient power for detecting the previously reported associations
at rs9275572 (power=94%), rs2596542 (power=92%) and
rs1012068 (power=94%). Taken together, the disparity of
associations may suggest the different genetic background of the
susceptibilities for HCV- and HBV-related HCC. Further studies
will be required to confirm the genetic heterogeneity of HCV- and
HBV-related HCC.
The association of rs9272105 (HLA-DQA1/DRB1)w i t hH B V
infection is consistent with the extensive reports on the association of
HLA-DRB1 with HBV infection where both protective and risk DRB1
alleles for HBV infection and outcome were identified [11,12,15–19].
Intriguingly,ourstudy hasrevealed thatthe variant allele ofrs9272105
showed a protective effect for HBV infection (OR=0.88) and the
progression to chronic symptomatic hepatitis B, but a risk effect for the
development of HCC (OR=1.30). Further studies will be needed to
demonstrate whether the opposite associations of HBV infection and
HBV-related HCC progression at rs9272105 are due to different
causal variants within the HLA class II region.
SNP rs455804 is located within the first intron of GRIK1 that is
the only gene within the LD region of the association (Figure 1B),
strongly implicating GRIK1 as a novel susceptibility gene for
HBV-related HCC. SNP imputation of the region did not reveal
any SNPs that showed stronger association than rs455804. GRIK1
encodes CLUR5, which is involved in the glutamate signaling, as
one of the ionotropic glutamate receptor, kainite 1 protein
(GLUR5), a subunit of ligand-activated channels and involved in
glutamate signaling. Our discovery of the association of GRIK1
with HCC has enhanced the emerging evidences for the important
role of glutamate signaling pathway in cancer development.
Glutamate has been shown to play a central role in the malignant
phenotype of gliomas through multiple molecular mechanisms
[20]. Inhibition of glutamate release and/or glutamate receptor
activity can inhibit the proliferation and/or invasion of tumor cells
in breast cancer [21], laryngeal cancer [22], and pancreatic cancer
[23], and ionotrpic glutamate receptor (GLUR6) was also
suggested to play a tumor-suppressor role in gastric cancer [24].
Recently, the exome sequencing analysis revealed that GRIN2A
(encoding the ionotrpic glutamate receptor (N-methyl D-aspartate)
subunit 2A) was mutated in 33% of melanoma tumors, clearly
indicating the involvement of glutamate signaling in melanoma
development. Finally, SNPs within GRIK1 have also been found
significantly associated with paclitaxel response in NCI60 cancer
cell lines, and may play a role in the cellular response to paclitaxel
treatment in cancer [25]. Consistent with the previous observa-
tions, our discovery of GRIK1 as a HBV-related HCC suscepti-
bility gene has suggested the importance of glutamate signaling in
HBV-related HCC development, and, although still speculative,
has highlighted the glutamate signaling pathway as a potentially
novel target for the treatment of HCC.
We also assessed the previously reported susceptibility locus
KIF1B on 1p36.22 (rs17401966) for HBV-related HCC [6]. Our
GWAS discovery analysis did reveal the consistent result for the
association at rs17401966, but the strength of association in our
GWAS discovery sample (OR=0.90) is much weaker than the
previously reported one (OR=0.61) (Table S8). SNP imputation
in our GWAS discovery samples did not reveal any stronger
association than the association at rs17401966 within the LD
region surrounding the 1p36.22 locus (Figure S6A).
Previous studies have clearly shown the existence of subpopu-
lation structure of Chinese Han population along the north-south
axis, and further demonstrated that geographic matching can be
used as a good surrogate for genetic matching, and PCA-based
correction is very effective in controlling the inflation effect of
population stratification [26]. In the current study, all the cases
and controls were matched by their geographic origin of residence.
Moreover, the GWAS discovery samples were from central and
southern China, while all the validation and replication samples
were from central China. Our PCA analysis indicates that while
there was mild population stratification in the sample of southern
China, the cases and controls from central China were well
matched without any indication of population stratification. In our
study, the PCA-based correction was used in the GWAS analysis,
and all the validation and replication analyses were from central
China. Therefore, our findings should be free of adverse effect of
population stratification in Chinese population.
In conclusion, the current GWAS identified two biologically
plausible, novel loci on 6p21.32 and 21q21 for HBV-related HCC.
These findingshighlightthe importance ofHLA-DQ/DRmolecules
and glutamate signaling in the development of HBV-related HCC.
Methods
Patient samples
The genome-wide discovery analysis was performed by
genotyping 731,442 SNPs in 1,575 HBV positive HCC patients
Table 2. Summary of the association results of five imputed
HLA alleles in the GWAS discovery samples.
CHR HLA-allele position OR
a P
a
6 HLA_DQA1_0301 32716284 0.85 4.39E-03
6 HLA_DQA1_0601 32716284 1.24 7.12E-03
6 HLA_DQB1_0401 32739039 0.71 4.49E-03
6 HLA_DRB1_0405 32660042 0.69 6.18E-04
6 HLA_DRB1_0901 32660042 0.85 1.46E-02
Conditional on HLA_DRB1_0405
6 rs9272105 32707977 1.28 8.99E-06
6 HLA_DRB1_0901 32660042 0.82 3.62E-03
6 HLA_DQA1_0301 32716284 0.90 8.78E-02
6 HLA_DQA1_0601 32716284 1.22 1.35E-02
6 HLA_DQB1_0401 32739039 0.89 4.77E-01
Conditional on HLA_DRB1_0405 and HLA_DRB1_0901
6 rs9272105 32707977 1.26 7.58E-04
6 HLA_DQA1_0301 32716284 1.14 2.35E-01
6 HLA_DQA1_0601 32716284 1.17 5.88E-02
6 HLA_DQB1_0401 32739039 0.87 4.13E-01
Conditional on the five HLA alleles
6 rs9272105 32707977 1.25 2.08E-03
Conditional on rs9272105
6 HLA_DRB1_0405 32660042 0.78 3.31E-02
6 HLA_DRB1_0901 32660042 1.02 7.90E-01
6 HLA_DQA1_0301 32716284 1.02 8.22E-01
6 HLA_DQA1_0601 32716284 1.08 4.04E-01
6 HLA_DQB1_0401 32739039 0.78 4.95E-02
aAdjusted by the first principal component.
doi:10.1371/journal.pgen.1002791.t002
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case-control cohorts of 500 cases and 500 controls from Central
China (Shanghai) and 1,075 cases and 990 controls from
Southern China (Guangdong). The first stage validation samples
included 2,112 HBV–positive cases and 2,208 HBV–positive
controls recruited from Jiangsu. The second stage validation
samples consisted of 1,021 HBV–positive cases and 1,491HBV
carriers recruited from Shanghai. The replication samples of
1,298 HBV–positive cases and 1,026 HBV carriers were recruited
from Central China (Shanghai and Jiangsu). (Table S1 and
Figure 1) All the samples are Han Chinese and partially
participated in the previously published studies [27,28]. The
diagnosis of HCC was confirmed by a pathological examination
and/or a-fetoprotein elevation (.400 ng/ml) combined with
imaging examination (Magnetic resonance imaging, MRI and/or
computerized tomography, CT). Because HCV infection is rare
in Chinese, we excluded HCC with HCV infection. Cancer-free
HBV+ control subjects from central China were recruited from
those receiving routine physical examinations in local hospitals or
those participating in the community-based screening for the
HBV/HCV markers and frequency-matched for age, gender,
and geographic regions to each set of the HCC patients. Almost
all these community-based controls are asymptomatic HBV
carriers. Similarly, cancer-free control subjects from southern
China are all HBV+, and 408 of them were asymptomatic HBV
carriers and 521 were symptomatic chronic hepatitis B patients.
All the HBV+ controls were positive for both HBsAg and
antibody to hepatitis B core antigen (anti-HBc), and negative for
anti-HCV.
We also recruited a HBV natural clearance cohort form Jiangsu
Province (Zhangjiagang and Changzhou cities) through a popu-
lation based screening for the HBV/HCV markers in 2004 and
2009, respectively (58,142 persons). Subjects with HBV natural
clearance were negative for HBsAg and anti-HCV, positive for
both antibody to hepatitis B surface antigen (anti-HBs) and anti-
HBc. About 9,610 subjects with HBV natural clearance were
identified. No history of hepatitis B vaccination was reported for
these people. Then, we randomly selected 1,344 HBV natural
clearance people without self-reported history of cancer in the
current study. The age for the 1,344 people were 52.6610.2 years,
and 217(16.2%) were females.
We collected smoking and drinking information through
interviews. Those who had smoked an average of less than 1
cigarette per day and less than 1 year in their lifetime were defined
as nonsmokers; otherwise, they were considered as smokers.
Individuals were classified as alcohol drinkers if they drank at least
twice a week and continuously for one year during their lifetime;
otherwise, they were defined as nondrinkers. At recruitment, the
informed consent was obtained from each subject, and this study
was approved by the Institutional Review Boards of each
participating institution.
Quality control in GWA Scan
We performed standard quality control on the raw genotyping
data to filter both unqualified samples and SNPs. The samples
with overall genotype completion rates ,95% were excluded
from further analysis (26 subjects). Eight subjects were excluded
as they showed discrepancy between the recorded and genetically
inferred genders. An additional 21 duplicates or probable familial
relatives were excluded based on the IBD analysis implemented
in PLINK (all PI_HAT.0.25). SNPs were excluded when they fit
the following criteria: (i) not mapped on autosomal chromosomes;
(ii) had a call rate ,95% in all GWA samples or in either of
Central cohort study or Southern study samples; (iii) had minor
allele frequency (MAF) ,0.05 in either of Central cohort study or
Southern study samples; and (iv) genotype distributions deviated
from those expected by Hardy-Weinberg equilibrium
(P,1610
25 in either of Central cohort study or Southern study
samples). We detected population outliers and stratification using
a principal component analysis (PCA) based method. After
removing MHC SNPs on chromosome 6 from 25–37 Mb, PCA
was performed by using common autosomal SNPs with low LD
(r
2,0.2) in the reference samples of the HapMap project (YRI
(n=90), CEU (n=90), CHB (n=45) and JPT (n=44)) as the
internal controls and our 3,010 participants of the GWAS
discovery samples (after removal of samples with low call rates,
ambiguous gender, and familial relationships). Projection onto
the two multidimensional scaling axes is shown in Figure S2A. 7
outliers (more than 6 standard deviations) were identified and
excluded. Finally, 523,663 autosomal SNPs in 1,538 cases and
1,465 controls, consisting of 480 cases and 484 controls from
Central China and 1,058 cases and 981 controls from Southern
China, were retained for association testing (Table S1).
SNPs selection and genotyping in validation phases
SNPs for the first stage validation were selected based on the
following criteria: (i) SNP had P joint#1.0610
24 in the analysis of
the combined GWA samples or either the Central China sample
or the Southern China sample, and had a consistent association in
the two participant studies, meaning that the ORs from the two
samples are both either above or below 1; (ii) only SNP with the
lowest P value was selected when multiple SNPs showed a strong
LD (r
2$0.8). As a result, a total of 39 SNPs were included in the
first stage validation. 3 SNPs that were significantly associated with
HCC risk in the first validation stage were further genotyped in the
second stage validation samples. Genotyping in the two validation
samples were done by using the iPLEX platform (Sequenom) or
the TaqMan assays (Applied Biosystems). The primers and probes
were available upon request (Table S9). Laboratory technicians
who performed genotyping experiments were blinded to case/
control status. For TaqMan assay, ten percent of random samples
were repeated, and the reproducibility was 100%. The 2 validated
SNPs were genotyped in another independent replication using
the same method.
Statistical analysis
Population structure was evaluated by the PCA in the software
package EIGENSTRAT 3.0 [26]. PCA revealed one significant
(P,0.05) eigenvector which was included in the logistic regression
with other covariates of age, gender, smoking and drinking status
for both the genome-wide discovery analysis and the joint analysis
of the combined discovery and replication samples. Ancestral
origin checking by PCA confirmed all the samples to be Han
Chinese and further demonstrated moderate genetic stratification
Figure 1. Regional plots of the susceptibility loci at rs9272105 on 6p and rs455804on 21q. rs9272105 on 6p (A); rs455804on 21q (B).The
association result (2log10P) is shown against the map position for each SNP within the region of 400 kb surrounding the validated association. The
marker SNPs of the associations are shown in purple, and the r
2 values of the rest SNPs with the marker one are indicated in different colors based on
the strengths. The annotated genes within the critical region of the association are shown in bottom.
doi:10.1371/journal.pgen.1002791.g001
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S2). The genome-wide association analysis was therefore
performed in logistic regression using PCA-based correction for
population stratification and by treating the samples of two
cohorts as independent studies. The genomic-control inflation
factor (lgc) after adjustment by the first PC was calculated for the
Central cohort samples (lgc=1.013), the Southern cohort
samples (lgc=1.003) and the combined GWAS discovery
samples (lgc=1.012). Consistently, the QQ plot of the observed
P values also showed a minimal inflation of genome-wide
association results due to population stratification (Figure S3).
Statistical analyses were performed by using PLINK 1.07 [29]
and R 2.11.1. The Manhattan plot of 2log10P was generated
using Haploview (v4.1) [30]. Untyped genotypes were imputed in
the GWAS discovery samples by using IMPUTE2 [31] and the
haplotype information from the 1000 Genomes Project (ASN
samples as the reference set) and HapMap3 (CHB and JPT
samples as the reference samples). The regional plot of association
was created by using an online tool, LocusZoom 1.1. P value was
two-sided, and OR presented in the manuscript was estimated by
using additive model and logistic regression analyses if not
specified.
To impute classical HLA alleles, we used 180 phased haplotypes
from the HapMap CHB and JPT samples as our reference panel.
This panel comprised dense SNP data and HLA allele types at 4-
digit resolution for the HLA class I (HLA-A, B, C) and II (DQA1,
DQB1 and DRB1) genes as previously described [32]. Genotypes,
probability and allelic dosages were then imputed separately in the
two discovery samples of Central and Southern Chinese using the
BEAGLE program. Association testing was performed by using a
logistic regression model on the best-guessed genotypes and allelic
dosages. The results were checked for consistency between the two
methods, and the results from best-guessed genotypes were
presented.
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